LISATA THERAPEUTICS, INC.
LSTA · XNASCIK 320017fmd_1H6T89EAFQR4W35SP7QRAGPFSCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 35 | – | – | – | – | – | 0 | 0 | 1 | 0 |
| Cost of revenue | 31 | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 4 | – | – | – | – | – | – | – | – | – |
| Research and development | 17 | 16 | 8 | 11 | 9 | 18 | 13 | 13 | 11 | 8 |
| Selling, general and administrative | 13 | 12 | 9 | 9 | 10 | 11 | 14 | 13 | – | – |
| Total operating expenses | 30 | 28 | 17 | 20 | 19 | 29 | 58 | 26 | 23 | 18 |
| Operating income | (30) | (28) | (17) | (20) | (19) | (29) | (58) | (26) | (22) | (18) |
| Interest expense | 2 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | (0) | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 1 |
| Income before taxes | (31) | (28) | (16) | (19) | (19) | (29) | (57) | (23) | (21) | (18) |
| Income tax expense | 0 | (12) | 0 | 0 | (11) | (2) | (2) | (2) | (1) | (1) |
| Net income from continuing operations | (31) | (16) | (16) | (19) | (8) | (27) | (54) | (21) | (20) | (17) |
| Net income | (33) | 23 | (16) | (19) | (8) | (27) | (54) | (21) | (20) | (17) |
| Net income to common shareholders | (33) | – | – | – | – | – | – | – | – | – |